key: cord-0907122-v4g26izh
authors: Widera, M.; Wilhelm, A.; Hoehl, S.; Pallas, C.; Kohmer, N.; Wolf, T.; Rabenau, H. F.; Corman, V. M.; Drosten, C.; Vehreschild, M. J.; Goetsch, U.; Gottschalk, R.; Ciesek, S.
title: Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro
date: 2021-02-26
journal: nan
DOI: 10.1101/2021.02.24.21252372
sha: 3a2cb2e9e15f2fedd171aa49ab52ef1664ad4572
doc_id: 907122
cord_uid: v4g26izh

The IgG1 monoclonal antibody (mAb) bamlanivimab (LY-CoV555) prevents viral attachment and entry into human cells by blocking attachment to the ACE2 receptor. However, whether bamlanivimab is equally effective against SARS-CoV-2 emerging variants of concern (VOC) is not fully known. Hence, the aim of this study was to determine whether bamlanivimab is equally effective against SARS-CoV-2 emerging VOC. The ability of bamlanivimab to neutralize five SARS-CoV-2 variants including B.1.1.7 (mutations include N501Y and del69/70), B.1.351 (mutations include E484K and N501Y) and P.2 (mutations include E484K in the absence of a N501Y mutation) was analyzed in infectious cell culture using CaCo2 cells. Additionally, we analyzed vaccine-elicited sera after immunization with BNT162b2, and convalescent sera for its ability to neutralize SARS-CoV-2 variants. We found that the variant B.1.1.7, as well as two isolates from early 2020 (FFM1 and FFM7) could be efficiently neutralized by bamlanivimab (titer 1/1280, respectively), however, no neutralization effect could be detected against either B.1.135 or P.2, both harboring the E484K substitution. Vaccine-elicited sera showed slightly decreased neutralizing activity against B1.1.7, B.1.135 and P.2 Our in vitro findings indicate that, in contrast to vaccine-elicited sera, bamlanivimab may not provide efficacy against SARS-CoV-2 variants harboring the E484K substitution. Confirmation of the SARS-CoV-2 variant, including screening for E484K, may be needed before initiating mAb treatment with bamlanivimab to ensure both efficacious and efficient use of the antibody product. Hence, variant-specific mAb agents may be required to treat emerging VOC.

The IgG1 monoclonal antibody (mAb) bamlanivimab (LY-CoV555) prevents viral attachment and entry into human cells by blocking attachment to the ACE2 receptor. However, whether bamlanivimab is equally effective against SARS-CoV-2 emerging variants of concern (VOC) is not fully known. Hence, the aim of this study was to determine whether bamlanivimab is equally effective against SARS-CoV-2 emerging VOC. The ability of bamlanivimab to neutralize five SARS-CoV-2 variants including B.1.1.7 (mutations include N501Y and del69/70), B.1.351 (mutations include E484K and N501Y) and P.2 (mutations include E484K in the absence of a N501Y mutation) was analyzed in infectious cell culture using CaCo2 cells. Additionally, we analyzed vaccine-elicited sera after immunization with BNT162b2, and convalescent sera for its ability to neutralize SARS-CoV-2 variants.

We found that the variant B.1.1.7, as well as two isolates from early 2020 (FFM1 and FFM7) could be efficiently neutralized by bamlanivimab (titer 1/1280, respectively), however, no neutralization effect could be detected against either B.1.135 or P.2, both harboring the E484K substitution. Vaccine-elicited sera showed slightly decreased neutralizing activity against B1.1.7, B.1.135 and P.2

Our in vitro findings indicate that, in contrast to vaccine-elicited sera, bamlanivimab may not provide efficacy against SARS-CoV-2 variants harboring the E484K substitution. Confirmation of the SARS-CoV-2 variant, including screening for E484K, may be needed before initiating mAb treatment with bamlanivimab to ensure both efficacious and efficient use of the antibody product. Hence, variant-specific mAb agents may be required to treat emerging VOC.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Recently, bamlanivimab has been authorized by the FDA for emergency use in early mild to moderate COVID-19 disease.

Emerging "variants of concern" SARS-CoV-2 referred to as B. is not yet known whether bamlanivimab is equally effective against these emerging "variants of concern". In this study, we examined the ability of bamlanivimab, vaccine-elicited sera after immunization with BNT162b2, and convalescent sera, to neutralize the emerging SARS-CoV-2 variants B.1.1.7 (mutations include N501Y and Δ69/70), B.1.351 (mutations include E484K and N501Y) and P.2 (mutations include E484K in the absence of a 501 mutation). These isolates have been obtained from travelers from Great Britain, South Africa and Brazil, respectively. Two SARS-CoV-2 isolates collected in early 2020 were also tested (FFM1, FFM7)(5, 6).

The mAb working solution was serially diluted 1:2 and incubated with 4000 TCID 50 / ml of each SARS-CoV-2 isolate, and subjected to Caco2 cell based SARS-CoV-2 neutralization assay.

The corresponding sample dilution resulting in 50% virus neutralization titer (NT 50 ) was determined. After 3 days of incubation cells were evaluated for the presence of a cytopathic effect (CPE).

The variant B.1.1.7, as well as the isolates from early 2020 (FFM1 and FFM7), could be efficiently neutralized by bamlanivimab (titer 1/1280, respectively) (table 1). However, no neutralization effect could be detected against either B.1.135 or P.2, both harboring the E484K substitution. Spike protein alignments confirmed that only E484K substitution occurs exclusively in the two strains that could not be neutralized by bamlanivimab.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Vaccine-elicited sera showed neutralizing activity against FFM1 and FFM7, and slightly decreased activity against B1.1.7, B.1.135 and P.2 (table 1). In one exceptional case of serum from an individual who was vaccinated after convalescence, high titers that were equivalent to the monoclonal antibody preparation were observed. Convalescent sera had lower neutralizing activity against "variants of concern" when compared to the variants from early 2020, which may facilitate re-infection with emerging variants.

Our in vitro findings indicate that, in contrast to vaccine-elicited sera, bamlanivimab may not provide efficacy against SARS-CoV-2 variants harboring the E484K substitution. Our data was in agreement with previous studies using artificial pseudoviruses, showing that LY-CoV555 is ineffective against B.1.351 but is still effective against B.1.1.7 (7, 8) . However, this is the first study evaluating the neutralizing capacity of bamlanivimab (LY-CoV555) using live SARS-CoV-2 isolates.

We conclude that confirmation of the SARS-CoV-2 variant, including screening for E484K, may be needed before initiating mAb treatment with bamlanivimab to ensure both efficacious and efficient use of the antibody product. Variant-specific mAb agents may be required to treat emerging "variants of concern". Table 1: Neutralization titers against SARS-CoV-2 variants. The mAb solution was serially diluted (1:2) and incubated with 4000 TCID 50 / ml of the indicated SARS-CoV-2 variant. Caco2 cells subsequently inoculated and analyzed for a CPE formation after 72 h incubation. Values indicate SARS-CoV-2 microneutralization titer (NT 50 ), resulting in 50% virus neutralization. The values indicate mean values from two replicates per cell line. n= no neutralization. NC = negative control sera. * tested with SARS-CoV-2 IgG II Quant (Abbott Diagnostics, Delkenheim, Germany) using the automated Alinity i device. The quantitative assay is for the detection of -among others -neutralizing antibodies against the receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. Results are given as AU/mL (analytical measurement range: 21.0 -40 000.0). 

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell host & microbe

Neutralization of SARS-CoV-2 spike

/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

Optimized qRT-PCR Approach for the Detection of Intra-and Extra-Cellular SARS-CoV-2 RNAs

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. The New England journal of medicine

1.351 and B.1.1.7 to Antibody Neutralization

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination